The PennZone

  • Home
  • Non-profit
  • Education
  • Business
  • Construction
  • Technology
  • Entertainment
  • Travel
  • Health

Primrose Bio Announces Investment from 1315 Capital to Advance Manufacturing Solutions for Next-Generation Therapeutics
The PennZone/10273770

Trending...
  • New plusOne Research Finds the Orgasm Gap Is a 30-Point Chasm — and Confirms It Isn't Biology
  • AWARENESS TO WELLNESS: Imhotep Institute Charter High School
  • 5 Things NYC Courier Services Won't Tell You About How Same-Day Delivery Actually Works
SAN DIEGO, June 17, 2024 ~ In a recent announcement, Primrose Bio, Inc. revealed that it has received a significant equity investment from 1315 Capital, a healthcare-focused growth equity firm based in Philadelphia. This investment will provide the necessary funds for the company to further develop and expand its three major offerings.

Primrose Bio, Inc., also known as "Primrose," is dedicated to developing and licensing manufacturing technologies for nucleic acids and proteins used in therapeutics and vaccines. With this new investment, the company is well-positioned to advance its solutions for therapeutic protein and nucleic acid manufacturing with both current and future partners.

One of Primrose's key offerings is Prima RNApols™, which are proprietary RNA polymerase enzymes that have been shown to significantly improve mRNA manufacturing. These enzymes have been found to increase yields by up to 5 times, eliminate double-stranded RNA, and enhance cap incorporation compared to the commonly used T7 RNA polymerase standard.

Another major offering from Primrose is Pfenex Expression Technology®, a validated microbial expression system that has been used in five approved drugs. This technology consistently demonstrates 10-20 times higher yields compared to other systems such as E.coli, CHO, and yeast-based systems. It also boasts an unparalleled success rate in producing complex proteins.

More on The PennZone
  • Expanding Into High-Margin Battery Recycling With Black Mass Strategy plus Scaling AI Infrastructure & Global Supply Chain Platform: N A S D A Q: MWYN
  • Long-Distance Couples Spend Nearly $7,000 on Travel Before Moving In Together, New Mayflower Research Finds
  • Pittsburgh Author Embraces Wisdom in The Principal Thing
  • "I'm Sicka Church Too: Give Me Kingdom!" Ignites a Powerful Call for Healing and Truth
  • imggpt Launches AI-Powered GPT Image Generator and Photo Editor for Creative Teams

Lastly, Primrose offers PeliCRM®, the only commercially available CRM197 conjugate vaccine carrier protein used in approved products. This technology plays a crucial role in the production of vaccines.

Dr. Helge Zieler, CEO of Primrose Bio, Inc., expressed excitement about the partnership with 1315 Capital. "We are thrilled to have the support of such a high-quality organization and team at 1315 Capital who share our vision of expanding opportunities in biomanufacturing technologies for the pharmaceutical industry," he said.

Matt Reber, Partner at 1315 Capital, also shared his enthusiasm for this collaboration. "There has been a tremendous amount of innovation in therapeutics over the last decades, and relatively little in their production systems," he stated. "Primrose's validated technology platforms address an increasingly important challenge facing the industry as drugs get more complex, and pricing pressure continues to mount."

With this new investment, Primrose Bio, Inc. is poised to make significant strides in the biomanufacturing industry and continue to provide cutting-edge solutions for therapeutic protein and nucleic acid manufacturing.
Filed Under: Business

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Fulton County DA Fani Willis Officially Endorses Dr. Heavenly Kimes + Black Economic Agenda
  • Bellwether Farm Presents Kerry Hill Lamb to His Majesty King Charles III During Historic U.S. State Visit
  • Mr. T, Dafne Keen, Ron Perlman, Nick Apostolides, Angela Sant'Albano to FAN EXPO Philadelphia
  • New Study Finds Americans Judge Vacations on Value, Not Price — Signaling a Permanent Shift in How Travel Gets Booked
  • Pomona Organic Launches New Website, Surpasses 10 Million Bottles Sold, and Opens Affiliate Program to Creators
  • Postmortem Pathology Opens Sacramento Office Offering Private Autopsies for Families and Healthcare Investigations
  • Postmortem Pathology, a leading provider of private autopsies, has announced its expansion into the Las Vegas market
  • Kick'em Out Quick® Evictions Announces a New Endorsed Eviction Attorney in Atlanta / Fulton County, GA
  • Why Athletic Recovery Begins in the Nervous System
  • A Hidden Magical World Awaits in Ashley Gayheart's Upcoming Young Adult Fantasy, Rosewood Academy: The Awakening
  • Scott Ritsema of Bisnar Chase Selected for 2026 National Traumatic Brain Injury Association
  • Flint Youth Film Festival Shifts Gears, Becomes Vehicle City Film Festival
  • 62% of Gen X have no estate planning documents — Trust & Will research identifies "the Sandwich Gap"
  • Nayarit's Jungle Coast Redefines Luxury Travel on Mexico's Pacific Now More Accessible Than Ever
  • $10 Million Annual Revenue Merger, Profitable Partner in AI Powered Specialty Automotive Sales Projected to Scale Above $200M: Stock Symbol: NWPG
  • Virginia Moving Company Nearly Doubles Customer Calls in Two Weeks After Switching to CARL — the Bold New Alternative to WordPress
  • JR AIR TOOLS Launches Factory-Direct Air Hydraulic Jacks for Semi Trucks & Commercial Fleets
  • RAS AP Consulting Launches Vendor Master File & Payment Controls Assessment for NACHA Phase 2 Compliance
  • New Homesites Released at Heritage at Manalapan Featuring Scenic Golf Course Views
  • The Ultimate Solution to Halt Thermal Runaway

Popular on PennZone

  • 300 Episodes. One Mission: Brother Marcus Ignites a Global Movement of Inspiration - 130
  • The Finger Comb, a Dream Inspired 3-in-1 Styling Tool introduced by Andrea L. Randolph - 106
  • From Speech Therapy to 300+ Episodes: Brother Marcus Turns His Voice Into a Movement Launching a 24/7 Inspiration Radio Network on Day 100 of the Year
  • Attorney Joseph C. Kreps Files Lawsuit to Stop Alabama State Board of Pharmacy's Unlawful "Revenue-First" Rulemaking
  • Mensa Brings National Board Game Competition to Northern Virginia April 16-19
  • Porter's Day Care Empowers Philadelphia's Future Through 45+ Years of Excellence
  • Bishop Mary's WWDB 860 AM Show Nears Historic 250-Episode Milestone
  • Dog Grooming Businesses Turn to Performance-Based Platforms to Attract Local Clients
  • Heritage at South Brunswick Team Celebrates Major Wins at NJBA Sales and Marketing Awards
  • Eastern Adjustment Group, LLP Provides Property Loss Advocacy and Claim Support

Similar on PennZone

  • NRx Pharmaceuticals (N A S D A Q: NRXP) Accelerates Into National Spotlight as Manufacturing Launch, Federal Policy & AI-Driven Breakthroughs Converge
  • Expanding Into High-Margin Battery Recycling With Black Mass Strategy plus Scaling AI Infrastructure & Global Supply Chain Platform: N A S D A Q: MWYN
  • More Life Summit 2026 Announces Gary Brecka & Mr. Olympia Derek Lunsford as First Speakers for Miami Event
  • Bellwether Farm Presents Kerry Hill Lamb to His Majesty King Charles III During Historic U.S. State Visit
  • Postmortem Pathology Opens Sacramento Office Offering Private Autopsies for Families and Healthcare Investigations
  • Postmortem Pathology, a leading provider of private autopsies, has announced its expansion into the Las Vegas market
  • $10 Million Annual Revenue Merger, Profitable Partner in AI Powered Specialty Automotive Sales Projected to Scale Above $200M: Stock Symbol: NWPG
  • Virginia Moving Company Nearly Doubles Customer Calls in Two Weeks After Switching to CARL — the Bold New Alternative to WordPress
  • RAS AP Consulting Launches Vendor Master File & Payment Controls Assessment for NACHA Phase 2 Compliance
  • Strategic Talent Associates Launches THE ALIGNED RESET™
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us